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Primary aldosteronism (PA) comprises two main subtypes: unilateral aldosteronism, mainly caused by 28 
aldosterone-producing adenoma; and bilateral adrenal hyperplasia. Establishing the correct subtype in 29 
patients with PA is indispensible for choice of treatment. In addition to established methods, alternative 30 
tests are evolving for subtyping. Computed tomography (CT) and adrenal venous sampling (AVS) are 31 
currently recommended in the guidelines for the diagnostic work-up of patients with PA. CT cannot be 32 
used as a stand alone test for subtyping because of its limited accuracy but may be used in combination 33 
with other tests such as AVS or functional imaging. Nevertheless CT remains mandatory to exclude 34 
adrenocortical carcinoma. AVS provides the most accurate test to detect excessive secretion of 35 
aldosterone from an adrenal mass but has several practical limitations and disadvantages. Therefore 36 
alternative non-invasive and patient-friendly methods are required to determine the need for 37 
adrenalectomy. Functional imaging with specific molecular positron emission tomographic ligands is a 38 
potential alternative method that may replace AVS for patients with PA. The results of preliminary 39 
studies of 11C-metomidate are promising but ligands incorporating radionuclides with longer half-lives 40 
that selectively bind to CYP11B2 are needed. Steroid profiling provides another method for subtyping 41 
and selecting patients for adrenalectomy but this technology is in its infancy and prospective outcome-42 
based studies are required to determine if this technique may provide an alternative to AVS.  43 
 44 
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Among patients with primary aldosteronism (PA) excessive aldosterone secretion from a single adrenal 48 
may be caused by a unilateral adrenocortical aldosterone-producing adenoma (APA) (~40% of all cases 49 
of PA) or more rarely by unilateral hyperplasia. Bilateral aldosterone excess results from micronodular 50 
or macronodular hyperplasia and is designated as bilateral adrenal hyperplasia (BAH) (~60% of all cases 51 
of PA) [1, 2]. Due to differential expression of steroidogenic enzymes there can be variable secretion of 52 
steroids other than aldosterone. In particular, APAs often secrete higher amounts of corticosterone, 53 
deoxycorticosterone and the hybrid steroids, 18-hydroxycortisol and 18-oxocortisol, compared to 54 
adrenals of BAH patients [3]. 55 
Although the concept of the distinct nature of both subtypes is controversial, definitive and reliable 56 
distinction of unilateral and bilateral disease is imperative for therapeutic management of patients with 57 
PA. Unilateral disease is usually treated by adrenalectomy (ADX) whereas bilateral disease is treated 58 
using mineralocorticoid receptor antagonists. Therefore the primary goal of adequate subtyping is not 59 
just to determine the correct diagnosis but to select correctly the patients with unilateral disease who can 60 
be expected to benefit from surgery (i.e. those with the best chance of complete clinical and biochemical 61 
remission). As a histological diagnosis is only possible for the removed adrenal, the diagnosis in the 62 
other gland remains obscure. 63 
A conclusive final diagnosis of unilateral disease is feasible when the post-surgical follow-up data 64 
show complete biochemical cure [4]. Patients with bilateral disease (BAH) will not be intentionally 65 
operated and therefore a conclusive diagnosis can never be established for this group. A glimpse into 66 
the histopathology of BAH may be provided from patients operated for supposedly unilateral disease 67 
who subsequently show persistent aldosteronism following ADX. In addition some patients with BAH 68 
and ‘asymmetric’ aldosterone secretion may also undergo ADX as a consequence of their severe 69 
phenotype and a last resort for treatment [5].  70 
There are several methods potentially useful for differentiating unilateral (APA) from bilateral 71 
disease (BAH): 1. adrenal computed tomography (CT) or magnetic resonance imaging (MRI); 2. adrenal 72 
venous sampling (AVS); 3. targeted functional imaging using a radiolabeled metomidate PET tracer; 73 
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and 4. measurements of peripheral venous steroid profiles. Currently AVS is the only method 74 
recommended according to the Endocrine Society guideline to distinguish both subtypes and for 75 
selecting patients eligible for ADX [6]. Functional imaging and steroid profiling are evolving and 76 
promising methods but their true value for reliable subtyping requires validation. In this article we 77 
summarize these four methods and review their pro’s and con’s for their role in subtyping patients with 78 
PA.  79 
 80 
Anatomical imaging by CT and MRI  81 
Starting in the 1970’s when CT became available, this anatomic imaging modality enjoyed continuous 82 
use for locating adrenal adenomas in patients with a biochemical diagnosis of PA. CT is relatively 83 
inexpensive and non-invasive and provides high spatial resolution for imaging an adrenal mass. 84 
Subsequently MRI has provided an alternative anatomical imaging modality but apart from lack of 85 
radiation exposure carries no advantages over CT for subtyping PA patients [6].  86 
Multidetector CT scanning has several serious drawbacks for selecting PA patients for ADX (Table 87 
1). First, CT (and also MRI) provide an anatomical and not a functional diagnosis, so that these imaging 88 
modalities cannot establish whether an adrenal adenoma is actually the source of any excessive 89 
aldosterone production. This is important since non-functional adenomas are not uncommon, 90 
particularly with advancing age when prevalences increase to 10% in patients older than 50 years [7]. 91 
For this reason CT suffers from limited specificity. Diagnostic sensitivity remains also far from optimal. 92 
Although CT is generally reported to be unable to detect microadenomas (< 1 cm) with any degree of 93 
certainty, modern CT scans using thinner slices may detect microadenomas of less than 1 cm. Many 94 
APAs have a size of 1-2 cm but it has also been shown that adenomas of less than 1 cm account for 95 
nearly 25-50% of all APAs [8, 9]. Thus, a substantial number of patients with APAs who might be cured 96 
by ADX can be missed by CT.  97 
 98 
The value of CT for subtype diagnosis has been addressed in numerous studies, but most have been 99 
retrospective with poorly standardized clinical and biochemical follow-up criteria to classify outcomes. 100 
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Additionally, most studies used AVS as the reference standard. A systematic review showed that in 101 
nearly 38% of PA patients, results from CT or MRI indicated the incorrect APA or BAH subtype and 102 
would have resulted in inappropriate treatment [10]. Nevertheless, this high proportion was obtained 103 
under the assumption that AVS provides the perfectly correct subtype classification. As outlined later, 104 
this assumption is not fully justified. Nevertheless, in contrast to the outlined retrospective studies, a 105 
recent prospective study showed persistent PA in 9 of 46 patients (20%) who underwent ADX based on 106 
CT scan [11]. Volumetric analysis of the adrenal glands demonstrated, that mean adrenal gland volume 107 
in APA patients was not significantly different from BAH adrenal volume [12]. Moreover, volumes of 108 
the contralateral adrenal in APA patients were significantly larger in comparison to non-PA control 109 
adrenals.   110 
 Despite all above considerations, CT should still be carried out as the initial imaging test in PA 111 
patients for two reasons: a CT scan helps to rule out the occasional adrenocortical carcinoma that 112 
produces aldosterone [6]. Second, contrast enhanced CT provides useful information on the venous 113 
anatomy, which facilitates cannulation in those patients who need to undergo AVS [13, 14]. 114 
 115 
Adrenal venous sampling 116 
Adrenal venous sampling (AVS) is recommended by the Endocrine Society guideline to distinguish 117 
APA and BAH subtypes [6]. Except for young patients (<35 years) with clear-cut PA and an unilateral 118 
adenoma, all patients should undergo AVS to select those amenable for unilateral ADX. AVS is a 119 
functional test as opposed to CT and the concept that this technique is able to establish the source of 120 
aldosterone excess is intuitively very appealing. It is not surprising that use of AVS has shown a steep 121 
increase in major referral centres worldwide. This technique involves selective cannulation of the 122 
adrenal veins and one peripheral vein for measurements of plasma aldosterone and cortisol 123 
concentrations [15-17]. The technical success rates of correct adrenal vein cannulation is over 90% in 124 
hands of experienced radiologists and the reported complication rate is less than 2.5% [6]. 125 
Accurate placement of catheters is essential for reliable assessment of adrenal aldosterone 126 
secretion. However, selective cannulation, particularly of the right adrenal vein, is notoriously difficult 127 
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and complicated by considerable anatomic variations [14]. Commonly, the ratio of plasma 128 
concentrations of cortisol in the adrenal vein (AV) to a peripheral vein (PV) is used to verify and 129 
document accurate catheter placement. This ratio, also called selectivity index (SI), is calculated as 130 
cortisol AV/PV. An additional purpose of measuring cortisol is to correct for dilution from non-adrenal 131 
blood contamination. There are several drawbacks of using cortisol for these purposes. First, in 132 
comparison to aldosterone, cortisol is protein-bound (transcortin) and has a long circulating half-life. 133 
Thus, the step-ups in peripheral to adrenal vein cortisol concentrations are relatively modest and subject 134 
to interpretative error. An additional disadvantage is that some APAs can co-secrete cortisol [18, 19]. 135 
Potentially this may further invalidate the use of cortisol to determine the correct catheter position. 136 
Finally, cortisol is subject to pulsatile stress-mediated increments, thus impairing its usefulness for 137 
correct catheter positioning.  138 
To minimize stress induced variations in cortisol secretion, cosyntropin stimulation is used at many 139 
centers [20]. There are two advantages of cosyntropin stimulation: it increases the selectivity index and 140 
thereby the technical success rates of AVS and it obviates the need for simultaneous adrenal vein blood 141 
sampling. However, cosyntropin stimulation makes the procedure more complex, there is no consensus 142 
about the optimal stimulation protocol and in terms of outcome it is still controversial whether its use 143 
affects the accuracy of subtyping [16, 17].  144 
Since 2015 several alternatives to cortisol have been identified to provide improved assessment of 145 
of selectivity of adrenal vein sampling. Measurements of plasma metanephrine, the O-methylated 146 
metabolite of epinephrine, in particular show much larger step-ups from peripheral to adrenal venous 147 
plasma than cortisol and in many cases have clearly indicated selective sampling when measurements 148 
of cortisol suggested incorrect catheter placement [20]. Measurements of metanephrine is also 149 
particularly useful in for APAs that cosecrete cortisol [21, 22]. Since metanephrine is produced 150 
continuously within adrenal medullary cells from epinephrine leaking from chromaffin storage granules, 151 
a process that is independent of catecholamines secretion, these measurements should also not be 152 
affected by stress. Several steroids, including as dehydroepiandrosterone, androstenedione, 11-153 
deoxycortisol and 17-hydroxyprogesterone also produce much larger step-ups from peripheral to adrenal 154 
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venous plasma than cortisol and as such also provide superior biomarkers than cortisol to assess the 155 
selectivity of adrenal vein sampling [23-25]. It is time to give up on use of cortisol as an indicator of 156 
adrenal vein sampling selectivity. Apart from metanephrine and the four steroids outlined above, almost 157 
all steroids produced as part of the adrenal biosynthetic backbone produce higher selectivity indices than 158 
cortisol and are thereby also likely to offer superior assessments of correct catheter placement than 159 
cortisol [23]. 160 
Lateralization of aldosterone hypersecretion is currently commonly assessed by calculation of the 161 
lateralization index (LI) using the higher ratio of aldosterone to cortisol in one vein compared to the 162 
other. The cut-off level of the LI depends on whether cosyntropin stimulation is used or not but most 163 
centres use an LI of >4 to diagnose unilateral PA and of <3 to diagnose bilateral PA [16]. In patients 164 
with an LI between 3.0-4.0, lateralization can be diagnosed when the contralateral suppression index 165 
(defined as the ratio of aldosterone/cortisol between the non-dominant adrenal vein and a peripheral 166 
vein) is ≤1.0. Many centres use the contralateral suppression index as an extra criterium for lateralization 167 
but there are no outcome studies to show unequivocally that contralateral suppression is a useful 168 
diagnostic criterium [16, 20].    169 
There are several limitations to the AVS technique that need to be considered (Table 1). It is a 170 
complex, technically demanding, time consuming and an invasive technique that is not convenient for 171 
patients or medical staff [16, 17]. Invasiveness includes not only catheter manipulations but also 172 
exposure to radiation, although this depends on the proficiency of the interventional radiologist. More 173 
importantly, the procedure is not standardized and this applies in particular to the use of the cut-off 174 
levels to determine selectivity and lateralization. Lack of medical staff with the necessary technical 175 
expertise is one of the main reasons why AVS is insufficiently available to accommodate all patients 176 
that should undergo AVS according to the Endocrine Society guideline. Moreover, currently only a 177 
small fraction of hypertensive patients with PA are identified and if all patients with PA were actually 178 
identified through hypertensive population screening it is highly unlikely that any centre could cope 179 
with the subsequent demand for AVS. 180 
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An major consideration to all the above concerns the accuracy of AVS to establish the correct 181 
subtype of PA. The increasing use has gradually led to the contention that AVS is the ‘gold’ standard 182 
test but AVS has never been scrutinized according to the recommendations of the GRADE consortium 183 
[26]. Under conditions in which no ‘gold’ standard test is available, a prespecified outcome representing 184 
the benefits for the patients should be determined. In cases of patients who undergo ADX for unilateral 185 
disease (APA) the biochemical and clinical remission rates reflect the endpoints that determine the long-186 
term outcome for patients. The many published studies that reported on the diagnostic accuracy of AVS 187 
have a retrospective design with an inherent potential for bias. In addition, most studies suffered from 188 
incomplete or non-standardized follow-up data to assess outcome. Even more importantly, management 189 
of patients in comparative studies was determined by the result of AVS.  That AVS is not a ‘gold’ 190 
standard test can also be derived from recently published data. An international multicentre study using 191 
standardized follow-up data showed that the biochemical cure of 94% (range: 83-100) was lower than 192 
the 96-100% as published in a recent systematic review [27, 28]. A recently published randomized 193 
controlled outcome trial comparing management based on AVS versus CT could not establish a better 194 
clinical and biochemical outcome after one year of follow-up [11]. Although AVS is currently still the 195 
best performing test for subtyping of patients with PA, further and better designed studies are required 196 
to determine its true value for selecting patients with PA for ADX. 197 
 198 
Functional imaging using radiolabeled metomidate PET tracers 199 
Prior to the development of new radiolabeled tracers for molecular imaging, one of the first agents used 200 
for functional imaging of APAs was the norcholesterol derivative, 131I-6β-iodomethyl-19-201 
norcholesterol, also named NP-59 [29]. One retrospective study suggested that NP-59 might be helpful 202 
as functional imaging agent to select patients for ADX [30]. However, this was a small group of selected 203 
patients with PA in whom CT and AVS were inconclusive. This technique has major disadvantages that 204 
explain why this technique has been abandoned for subtyping patients with PA: it is time consuming, it 205 
is associated with a high radiation exposure (30 mSv) to the adrenal glands, the tracer is not widely 206 
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available and most importantly, uptake of the tracer is poor in small APAs and the spatial resolution to 207 
detect these small adenomas is insufficient, even if SPECT/CT imaging is used.  208 
In more recent years an extensive search has evolved for agents suitable for highly specific 209 
molecular PET imaging of adrenocortical tissue. One of the first agents was 11C-metomidate that has the 210 
capacity to bind with high specificity and avidity to the enzymes exclusively expressed in the adrenal 211 
cortex and involved in steroid synthesis, including CYP11B1 and CYP11B2 [31]. However 11C-212 
metomidate has a low selectivity for CYP11B2 over CYP11B1. This agent was shown to be potent for 213 
differentiating adrenocortical from non-adrenocortical tissue and has been used in several studies to 214 
identify the adrenal lesion [32].  215 
Several studies have assessed the diagnostic value of 11C-metomidate in patients with PA, but most 216 
studies were not designed to evaluate its role in subtyping [33]. One study addressed the value 11C-217 
metomidate PET/CT in patients with PA in a head-to-head design using AVS as the reference test [34]. 218 
The sensitivity and specificity of 11C-metomidate PET/CT, employing a ratio of tumor SUVmax 219 
(standardized uptake value) to normal adrenal background SUV of >1.25 for diagnosing APA, was 76% 220 
and 87% respectively. This small series of patients is promising but the applicability of this tracer is 221 
limited because one needs an on-site cyclotron due to the short 20 minute half-life of 11C. Radioisotopes 222 
with a longer half-life are more desirable. For subtyping of patients with PA, one would need a molecular 223 
tracer capable of binding specifically to CYP11B2 (aldosterone synthase). This is not only a crucial 224 
enzyme in aldosterone synthesis but its expression in smaller APAs is increased as compared to 225 
CYP11B1 (Table 1). Potential fluorine-18 labeling of such compounds will make them of practical use 226 
for PET scanning. Several new promising compounds for this purpose are currently under investigation 227 
in in vitro and in animal studies. A preliminary report of such compound (CDP2230) showed a more 228 
than 15 times higher selectivity for CYP11B2 over CYP11B1 compared to 11C-metomidate [35]. These 229 
data suggest that this compound has the potential to become a promising new agent for subtyping 230 
patients with PA. 231 
 232 
Steroid measurements 233 
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A new emerging method for subtyping of patients with PA involves measurements of additional steroids 234 
to aldosterone, including the hybrid steroids 18-hydroxycortisol and 18-oxocortisol. This has been 235 
fostered by the development of liquid chromatography with tandem mass spectrometry (LC-MS/MS) 236 
technology [36]. This technology is not only more accurate than immunoassays but enables 237 
simultaneous measurements of multiple steroids in a single sample [23].  238 
Several studies have examined whether adrenals from APAs and BAH are associated with a specific 239 
steroid signature as measured in urine or in adrenal venous plasma while more recently a few studies 240 
addressed the value of steroid profiling in a peripheral venous blood sample for subtyping. Some studies 241 
focused on one hormone, others used a panel of steroids.  242 
The first evidence that patients with APAs differed from patients with BAH in steroid secretion 243 
came from the group of Biglieri in 1979, showing that the use of a peripheral venous plasma 18-244 
hydroxycorticosterone level of >100ng/dL was highly predictive for an APA [37]. This could be 245 
confirmed several years later by other groups [38, 39]. More recently the basis for this finding was 246 
provided by a small study reporting a nearly 3-fold higher concentration of 18-hydroxycorticosterone in 247 
adrenal veins draining from APAs than in those from BAH [40]. The additional finding of a high 248 
concordance between the 18-hydroxycorticosterone/cortisol ratio and the aldosterone/cortisol ratio in 249 
the APA patients indicated however that measurement of 18-hydroxycorticosterone was not more useful 250 
for lateralization than aldosterone itself. Given the lack of larger prospective studies, measurement of 251 
18-hydroxycorticosterone in adrenal or peripheral venous plasma has not made its way into routine 252 
clinical practice and cannot be recommended for selecting patients for ADX. 253 
Most recently we carried out a retrospective study in a large group of 216 patients with PA, 254 
comprising 126 patients with an APA and 90 patients with BAH [41]. Aldosterone, 18-oxocortisol and 255 
18-hydroxycortisol were all higher in adrenal venous samples from APAs compared to BAH. The hybrid 256 
steroids were not overly helpful for lateralization as they showed lateralization in only 76% (n=90) (18-257 
oxocortisol) and 35% (18-hydroxycortisol) of cases where lateralization was apparent using aldosterone. 258 
Another retrospective study confirmed also higher 18-oxocortisol levels in adrenal blood from APAs 259 
           16/4/2019 
 
 11 
than BAH but found no evidence that the use of the 18-oxocortisol/cortisol ratio was superior to the 260 
aldosterone/cortisol ratio for subtyping patients with PA [42].      261 
As far back as 1992 Ulick and co-workers established that patients with APA showed higher urinary 262 
excretion of the hybrid steroids, 18-hydroxycortisol and 18-oxocortisol, than patients with BAH [43]. A 263 
later study that assessed both plasma and urinary steroids came to a similar conclusion although they 264 
noticed considerable overlap between both groups [39]. Although the sensitivity of the urinary 18-265 
hydroxycortisol excretion for the APA diagnosis was only 30%, an excretion rate of > 510 ug/day was 266 
diagnostic for APA, suggesting that such patients with proven PA and a unilateral adenoma on CT could 267 
be sent straight for ADX.   268 
There are a few retrospective studies that aimed to evaluate the role of steroids in a peripheral 269 
venous blood sample (Table 1). Satoh et al reported on 18-hydroxycortisol and 18-oxocortisol levels 270 
measured in peripheral venous samples using LC-MS/MS [44]. They established much higher plasma 271 
levels of both steroids in patients with APA than in those with BAH with relatively stronger increments 272 
for 18-oxocortisol (12.5 fold) than for 18-hydroxycortisol (2.5 fold). Plasma 18-oxocortisol displayed a 273 
sensitivity and specificity of 83% and 99% using a cut-off level of 4.7 ng/dL. All patients with an APA 274 
showed 18-oxocortisol levels of >1.2 ng/dL while no patient with BAH showed a level of >6.1 ng/dL. 275 
If combined with plasma aldosterone concentration, 84% of the patients with APA with a unilateral 276 
adenoma had a plasma aldosterone concentration of >32.7 ng/dL and a plasma 18-oxocortisol 277 
concentration of >6.1 ng/dL. These results suggest that in nearly 50% of all patients with PA, AVS could 278 
be circumvented because these patients could have been sent straight for ADX.  279 
The value of a peripheral venous steroid profile for predicting the correct subtypes (APA vs BAH) 280 
was reported in a recent large retrospective study of 216 patients with PA [41]. In 80% (172/216) of 281 
patients it was possible to classify the PA subtype correctly (based on post-ADX outcome as reference 282 
method) using a panel of 12 steroids (aldosterone, 18-oxocortisol, 18-hydroxycortisol, 11-dexycortisol, 283 
21-deoxycortisol, corticosterone, 11-deoxycorticosterone, progesterone, 17-hydroxyprogesterone, 284 
androstenedione, DHEA and DHEAS). This classification, shows promise but requires further 285 
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improvements. It should be noted however that that study used an AVS procedure with cosyntropin 286 
stimulation in some patients, thus potentially introducing bias.  287 
In a related study we measured a panel of 15 steroids in 79 patients with PA who were genotyped 288 
for mutations in the KCNJ5, ATP1A1, ATP2B3 and CACNA1D genes [45]. A remarkable finding was 289 
that the APAs with KCNJ5 mutations showed the highest peripheral plasma levels of 18-oxocortisol 290 
compared with all other mutations and the wild-type group. A subpanel of 7 steroids (aldosterone, 18-291 
oxocortisol, 18-hydroxycortisol, 11-deoxycorticosterone, corticosterone, cortisol, and 21-deoxycortisol) 292 
measured in peripheral venous plasma correctly predicted the genotype in 73 of 79 patients with APAs 293 
(92%). In 26/27 patients the presence of a somatic KCNJ5 mutation could be reliably predicted by the 294 
venous steroid profile. If validated this indicates that measurement of such a panel of 7 steroids may 295 
circumvent the need for AVS in patients with BAH because only patients with APA would require AVS 296 
to determine which adrenal gland overproduces aldosterone for selecting for ADX. The relatively small 297 
size and the retrospective nature of this study precludes any definite conclusions until these results are 298 
confirmed by a larger prospective study with standardized follow-up for outcome to verify the final 299 
subtype diagnosis. 300 
 301 
Conclusions and Perspectives 302 
Of the four discussed methods, CT and AVS are recommended for the diagnostic work-up of patients 303 
with PA. CT with its limited sensitivity and specificity cannot be used as a stand alone test but only in 304 
combination with other techniques such as AVS or functional imaging (PET scanning). CT scanning is 305 
nonetheless mandatory in every patient to exclude a potential adrenocortical carcinoma. AVS is a highly 306 
attractive test because it tests the functionality of an adrenal mass, even if small. This technique has 307 
however several limitations and disadvantages, urging the development and investigation of alternative 308 
non-invasive patient-friendly methods to determine which patients should be sent for ADX. Functional 309 
imaging with highly specific molecular PET ligands is a potentially promising method that may replace 310 
AVS in some or even all patients. Although the results of preliminary studies of 11C-metomidate are 311 
encouraging, more specific and fluorinated ligands that selectively bind to CYP11B2 are needed. Steroid 312 
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profiling as a method for subtyping and selecting patients for ADX is still in its infancy and more 313 
prospective outcome-based studies are required to see if this technique is a better alternative to AVS.  314 
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Table 1.  327 
Advantages and disadvantages of the methods for subtyping of patients with primary aldosteronism 328 
 Advantages Disadvantages 
Computed tomography 
- widely available 
- non-invasive  
- high spatial resolution 
- relatively cheap 
- not specific: anatomical information 
- limited sensitivity 
- radiation exposure moderate 
- contraindication if contrast allergy  
Adrenal venous sampling 
- functional test 
- highly predictive of outcome 
 
- limited availability 
- laborious and technically demanding 
- not-standardized procedure 
- radiation exposure significant 
- contraindication if contrast allergy 
Metomidate imaging 
- proof of principle   
- specific binding to CYP11B2 
- non-invasive technique 
- limited availability (cyclotron needed) 
- radiation exposure moderate 
- lower selectivity of binding to CYP11B2    
  than to CYP11B1 
- very limited data available 
Steroid profiling 
- non-invasive 
- high specificity (LC-MS/MS)  
-  multiple hormones (one assay) 
- convenient: one blood sample 
- LC-MS/MS: expensive 
- LC-MS/MS expertise required 
- no prospective data available 
- interpretation of results: expertise needed 
 329 
LC-MS/MS, liquid chromatography with tandem mass spectrometry  330 
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